GOVX
$1.68
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preve...
Recent News
How The Story On GeoVax Labs (GOVX) Is Shifting Toward Execution Risk And Funding Constraints
The updated fair value estimate for GeoVax Labs holds steady at about US$270.83 per share, signaling no change to the central price target in the current model. That stability comes as analysts adopt a more cautious tone, with enthusiasm around the GEO-MVA program now balanced by concerns over execution, funding, and a thinner set of near term catalysts. As you read on, you will see how this evolving narrative might shape your view of the stock over time and what to watch next. Analyst Price...
Siga Technologies Q4 Earnings Call Highlights
Siga Technologies (NASDAQ:SIGA) reported 2025 results and provided a business update focused on its role in global smallpox preparedness, highlighting product deliveries under its current U.S. government contract, ongoing development programs, and expectations around a European regulatory review for
Shopify, eBay upgraded: Wall Street's top analyst calls
Shopify, eBay upgraded: Wall Street's top analyst calls
Geovax Labs Inc (GOVX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Geovax Labs Inc (GOVX) navigates a complex landscape with promising vaccine developments and strategic discussions, despite facing revenue declines and funding hurdles.
GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?
GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).